Brazil medical education giant Afya surges amid major US-listed merger

Brazilian medical education giant Afya Limited saw its shares climb 4.24% on Friday, closing at $14.75 on the Nasdaq. The movement highlights a unique corporate structure: unlike most Brazilian companies that trade in New York via American Depositary Receipts (ADRs), Afya is one of the few Brazilian enterprises with a primary, direct listing in the United States. This setup allows international retail investors to trade its shares directly, bypassing the typical fees and administrative layers associated with ADRs.

The stock’s upward momentum comes at a pivotal moment for the Belo Horizonte-based company. On September 23, 2026, Afya announced a binding merger agreement with Yduqs Participações S.A., one of Brazil’s largest higher education conglomerates. Under the terms of the deal, the two entities will combine to form a massive higher education powerhouse in Latin America. However, the transaction carries a major structural shift for US-based retail investors: upon completion, Afya’s Class A common shares will be delisted from the Nasdaq, and the newly combined company will trade exclusively on the Brazilian B3 exchange.

Afya has built a highly profitable niche by addressing Brazil's stark regional healthcare disparities. The company operates 32 campuses, focusing heavily on acquiring and developing medical schools in underserved, remote regions of the country. According to the International Finance Corporation (IFC), which has backed the group with sustainability-linked loans, roughly 70% of Afya's graduates choose to remain and practice in these low-income communities. Beyond undergraduate degrees, the company's digital platform and continuing education courses serve approximately one-third of all active physicians in Brazil.

The pending merger with Yduqs is designed to consolidate this dominant position, giving the combined company immense scale in both specialized medical training and general higher education. Under the agreed exchange ratio, Afya's shareholders will own 69% of the combined entity, with German media giant Bertelsmann holding a 47.4% controlling stake.

While the business combination promises significant operational synergies, it also introduces a transition timeline that international investors are watching closely. The deal is subject to regulatory approvals in Brazil, including clearance from the Administrative Council for Economic Defense (CADE), the national antitrust watchdog. Until the transaction officially closes and the Nasdaq delisting occurs, Afya remains a highly visible gateway for foreign capital targeting Brazil's private healthcare and education sectors.

What it touches

The corporate consolidation directly impacts US investors holding Afya Limited (NASDAQ: AFYA). Because the post-merger entity will list exclusively on the Brazilian B3 exchange, current US retail shareholders will eventually see their Nasdaq shares converted into Brazilian-listed equities. This transition exposes foreign retail accounts to local currency fluctuations between the US dollar and the Brazilian real, as well as the regulatory environment of Brazil's financial markets.